Company intelligence / Profile preview
DigmBio
Pangyo, Gyeonggi-do, South Korea
- Ownership
- Private
- Development stage
- Other
01
Overview
DigmBio's PARP1 inhibitor (DM5167) exhibits superior in vivo safety and selectivity compared to existing drugs; excellent brain permeability supports expanded indications such as brain metastasis. IND approval granted for Phase 1 trial in Korea; preclinical studies show promising anti-tumor efficacy.
- Therapeutic areas
- OncologyNeurologyOther
- Modalities
- Small moleculeMolecular glue therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
BioDuro-Sundia (CRO partner)Chung Nam University and Kukje Pharma (In-licensed candidate)
Beyond the preview
Go deeper on DigmBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DigmBio.